Table 2. Various Studies Reported the Patient’s Delay of Diagnosis.

		Mean delay, month	< 1 month	1 - 3 month	3 - 6 month	6 - 12 month	> 12 month	No delay
Basnet et al, 2018 [35]	National Cancer Data Base (NCDB) (n = 313,329)	-	59.05%	31.89%	-	9.05%	-	-
Xavier et al, 2016 [31]	Brazil (n = 211)	5	16.6%, (n = 35)	17.1%, (n = 36)	11.8%, (n = 25)	8.1%, (n = 17)	18%, (n = 38)	28.4%, (n = 60)
Tyler et al, 2005 [32]	Canada (n = 176)	4.7	50%, (n = 88)		19.3%, (n = 34)		51.1%, (n = 9)	19.9%, (n = 35)
Betti et al, 2003 [30]	Italy (n = 216)	6.1	-	-	-	-	-	26.6%, (n = 57)
Richarde et al, 1999 [36]	France (n = 590)	2	23.10%, (n = 136)	17.60%, (n = 104)	13.40%, (n = 79)	8.50%, (n = 50)	8.30%, (n = 49)	29.2%, (n = 172)
Rampen et al, 1989 [37]	The Netherlands (n = 284)	-	6.7%, (n = 19)	16.9%, (n = 48)	15.8%, (n = 45)	16.9%, (n = 48)	33.6%, (n = 95)	10.3%, (n = 29)
Doherty er al, 1986 [38]	Scotland (n = 25)	-	16%, (n = 20)		50.4%, (n = 55)		33.6%, (n = 42)
Krige et al, 1991 [39]	South Africa (n = 250)	9.8	16.8%, (n = 42)	18%, (n = 45)	22%, (n = 55)	15.2%, (n = 38)	16.4%, (n = 41)	11.6%, (n = 29)
Schmid-Wendtner et al, 2002 [40]	Germany (n = 233)	-	15.5%, (n = 36)	16.7%, (n = 39)	14.6%, (n = 34)	11.6%, (n = 27)	29.20%, (n = 68)	12.4%, (n = 29)